Evidence map›Paper›PMID 42589442›Full record

ArticleInternational journal of molecular sciences2026

MicroRNA Signatures of Fulvestrant-Treated Luminal Breast Cancer Cells: Identification of Therapeutic Targets Regulated by

Ayako Nagata, Yuya Tomioka, Ryutaro Yasudome, Hiroko Toda, Takuya Tokunaga, Yuki Nagata, Mayuko Kato, Yoshiaki Shinden, Akihiro Nakajo, Naohiko Seki

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ayako NagataDepartment of Breast and Thyroid Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8544, Japan.ORCID 0000-0001-8735-3383
Yuya TomiokaDepartment of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8544, Japan.ORCID 0009-0006-7067-5064
Ryutaro YasudomeDepartment of Breast and Thyroid Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8544, Japan.ORCID 0000-0003-1221-5239
Hiroko TodaDepartment of Breast and Thyroid Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8544, Japan.
Takuya TokunagaDepartment of General Thoracic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8544, Japan.ORCID 0009-0008-1885-5775
Yuki NagataDepartment of Digestive Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8544, Japan.
Mayuko KatoDepartment of Functional Genomics, Chiba University Graduate School of Medicine, Chuo-ku, Chiba 260-8670, Japan.ORCID 0009-0004-9511-6977
Yoshiaki ShindenDepartment of Breast and Thyroid Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8544, Japan.
Akihiro NakajoDepartment of Breast and Thyroid Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8544, Japan.
Naohiko SekiDepartment of Functional Genomics, Chiba University Graduate School of Medicine, Chuo-ku, Chiba 260-8670, Japan.ORCID 0000-0003-4731-7956

Funding

Japan Society for the Promotion of Science 24K19396Japan Society for the Promotion of Science 26K11545Japan Society for the Promotion of Science 26K11546
6 · The paper itself

Abstract

Estrogen receptor (ER)-positive breast cancer (BrCa) accounts for two-thirds of all BrCa cases worldwide. Therefore, ER-targeted endocrine therapy is the standard treatment for this disease. There has been a recent trend towards developing combination therapies using molecularly targeted drugs to improve outcomes. This study aimed to identify therapeutic targets demonstrating efficacy when combined with fulvestrant (a selective ER downregulator/degrader). We generated microRNA (miRNA) signatures from fulvestrant-treated MCF-7 cells by RNA sequencing. From the signature, we evaluated

Indexed as

Breast NeoplasmsFulvestrantGene Expression Regulation, NeoplasticMicroRNAsAntineoplastic Agents, HormonalCell Line, TumorCell ProliferationFemaleGene Expression ProfilingHumansMCF-7 CellsAntineoplastic Agents, HormonalFulvestrantMicroRNAsMIRN374 microRNA 374, humanbreast cancerestrogen receptorFOXM1fulvestrantmicroRNAmiR-374b-5p

Identifiers

PMID42589442
PMCPMC13466626

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.